Sector News

Sanofi drops the ax on 100 R&D staffers in Boston reorganization

February 11, 2015
Life sciences
Just as it was spreading word of a big new development partnership this morning, Sanofi dropped the ax on about 100 employees in a reorganization of its R&D operations.
 
Rumors of the layoffs started circulating in the big Boston biotech hub later in the morning, and a spokesperson for Sanofi ($SNY) confirmed the cuts to FierceBiotech mid-day. The company made its cuts in oncology and global R&D, he said, sending word internally this morning.
 
“Sanofi communicated a natural evolution of its research and development organization that will prioritize its focus and investments in exciting areas of science and medicine,” according to a company statement.
 
The layoffs in oncology mark an acknowledgement of Sanofi’s struggle to develop new cancer treatments. Bloomberg reports that Tal Zaks, who had led the group, is out in the reorganization. And the wire service adds that oncology is being absorbed into global R&D as it tries to catch the next wave in cancer drug development.
 
Sanofi has faced considerable turmoil in recent months, after CEO Chris Viehbacher was suddenly ousted following a cut in the company’s forecasted revenue, a move that left Chairman Serge Weinberg in charge and in search of a new CEO. Sanofi spent more than $20 billion to acquire Genzyme almost exactly four years ago, carving out a big place for itself in the Boston/Cambridge supercluster. But Sanofi also faced the embarrassing writeoff of iniparib in 2013, an early sign that the company’s cancer R&D strategy was going astray.
 
Sanofi has had a mixed record in R&D since Viehbacher set out on a campaign to reorganize the company, becoming a proponent for major changes after seeing little in the way of innovation. An attempt to make cuts in France, though, was blunted by government and union officials. Internal R&D overall has a poor track record. Where Sanofi has performed well is in partnering, with a very close relationship with Regeneron that has paid off with some closely watched development efforts.
 
Sanofi followed up with new collaborations, like the one announced today with Voyager Therapeutics to explore new gene therapies for CNS diseases. That deal included $100 million upfront, and up to $745 million in milestones.
 
By John Carroll
 

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.